Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Launched by SIMON WILLIAMSON CLINIC · Oct 1, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on finding better ways to prevent nausea and vomiting that can occur after chemotherapy, particularly for patients who are receiving treatments known to cause these side effects. The study specifically targets patients who experienced breakthrough nausea and vomiting after their first round of treatment and are about to start their second cycle of moderately or highly emetogenic chemotherapy. The goal is to improve their comfort and quality of life during treatment.

To be eligible for this trial, participants should be between the ages of 65 and 74, have lung or breast cancer, and have not received chemotherapy before. Importantly, they should not have experienced nausea or vomiting within 24 hours before joining the study. If you decide to participate, you can expect to receive a treatment plan that aims to better manage any nausea and vomiting you might experience during your chemotherapy cycles. This research is currently looking for volunteers who meet these criteria, so if you or someone you know is interested, it could be a great opportunity to help improve cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • CHEMOTHERAPY NAIIVE
• • patient receiving moderately or highly emetogenic chemotherapy
• • lung cancer
• • breast cancer
• Exclusion Criteria:
• • PRIOR CHEMOTHERAPY for any cancer
• • nausea or vomiting 24 hours prior to study entry